Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

AbbVie and Tentarix partner to develop oncology and immunology biologics

The collaboration will use Tentarix's proprietary platform to develop biologics against two targets

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

Biogen Idec building

Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients

The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals

- PMLiVE

AbbVie announces NICE recommendation for blood cancer therapy Tepkinly

Around 5,500 new cases of diffuse large B-cell lymphoma are diagnosed in the UK every year

Biogen Idec building

Biogen to discontinue Alzheimer’s drug Aduhelm in favour of Eisai-partnered Leqembi

The post-marketing confirmatory study of the intravenous treatment will now be terminated

- PMLiVE

AbbVie and Umoja announce CAR-T cell therapy agreements worth over $1.4bn

One of the deals gives AbbVie licensing rights to Umoja's CD19-directed therapy for blood cancers

- PMLiVE

AbbVie to expand neuroscience pipeline with $8.7bn Cerevel Therapeutics acquisition

The deal includes a candidate currently in phase 3 testing as a treatment for Parkinson’s disease

- PMLiVE

AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

AbbVie announces positive results from head-to-head study of Skyrizi in Crohn’s disease

The late-stage trial has been evaluating the IL-23 inhibitor against Johnson & Johnson’s Stelara

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links